A purine compound, its preparation method and application
By introducing specific groups into purine compounds to form novel skeletal structures, and using nucleophilic substitution and Suzuki coupling reaction methods, the problem of insufficient selectivity of existing LSD1 inhibitors has been solved, achieving highly selective and reversible LSD1 inhibitory activity, thus promoting the development of anti-tumor drugs.
Patent Information
- Application Number
- CN202611395114.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-09
- Publication Date
- 2026-11-17
AI Technical Summary
Existing LSD1 inhibitors suffer from insufficient selectivity, off-target effects, and potential dose-limiting toxicity. Furthermore, the types of reversible inhibitor skeletons are limited, and their inhibitory activity and in vivo efficacy need to be improved.
A purine compound was designed by introducing a phenyl, substituted phenyl, five-membered heterocyclic or six-membered heterocyclic group at the 2-position of the purine and an aniline, aromatic or aliphatic amine group at the 6-position to form a novel skeletal structure. The compound was prepared by nucleophilic substitution and Suzuki coupling reaction.
It provides highly selective and reversible LSD1 inhibitory activity, offering a novel structural framework for the development of highly effective anti-tumor drugs, and showing good drug development potential.
Smart Images

Figure CN123106679A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of organic synthesis technology, and particularly relates to a purine compound, its preparation method, and its application. Background Technology
[0002] Epigenetic modifications regulate gene expression homeostasis through mechanisms such as DNA methylation and histone modifications. Histone lysine-specific demethylase 1 (LSD1 / KDM1A) is the first discovered flavin adenine dinucleotide (FAD)-dependent histone demethylase, specifically catalyzing the demethylation of H3K4me1 / 2 and H3K9me1 / 2, thereby regulating gene transcription through chromatin remodeling. Studies have shown that LSD1 is abnormally highly expressed in various malignant tumors (such as prostate cancer, breast cancer, small cell lung cancer, esophageal cancer, neuroblastoma, and acute myeloid leukemia), promoting tumor proliferation, invasion, and metastasis by activating oncogenes or silencing tumor suppressor genes; its high expression is often associated with poor patient prognosis. In recent years, LSD1 has also been found to participate in tumor immune escape, weakening CD8 by downregulating MHC-I expression. + T cell-mediated anti-tumor immune response.
[0003] Currently, several LSD1 inhibitors have entered clinical trials, but most are irreversible covalent inhibitors based on tranylcyclopropane. These compounds exert their effects by covalently binding to the FAD cofactor, and suffer from problems such as insufficient selectivity, off-target effects, and potential dose-limiting toxicity. While reversible inhibitors avoid the safety risks associated with covalent modification, the existing reversible inhibitor backbone types are limited, and their inhibitory activity and in vivo efficacy still need to be improved.
[0004] Therefore, how to provide a highly selective and reversible LSD1 inhibitor based on a novel scaffold to overcome the current bottleneck of epigenetic targeted therapy and provide a new approach for the immunotherapy of LSD1-related tumors (especially esophageal cancer) is a technical problem that urgently needs to be solved by those skilled in the art. Summary of the Invention
[0005] To address the aforementioned technical problems, this invention proposes a purine compound, its preparation method, and its applications.
[0006] To achieve the above objectives, the present invention provides the following technical solution: A purine compound, the structural formula of which is shown in Formula I: ; Wherein, the R 1 Selected from phenyl, substituted phenyl, five-membered heteroaryl, or six-membered heteroaryl; X is selected from NH, NMe, or does not exist; When X is NH or NMe, R2 Selected from aryl or substituted aryl; When X does not exist, R 2 Selected from nitrogen-containing heterocyclic groups that can be directly linked to the purine nucleus.
[0007] Preferably, the R 1 Selected from , , , , , , , , , , , , , , , , , , , , , , , and One of them.
[0008] Preferably, the R 2 Selected from , , , , , , , , , and One of them.
[0009] More preferably, purine compounds include the following compounds: A method for preparing a purine compound, comprising the following steps: (1) 2,6-Dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine was subjected to a nucleophilic substitution reaction with an amine compound under alkaline conditions to obtain intermediate 1d; (2) The intermediate 1d was coupled with the boric acid substrate under the action of base and palladium catalyst in a Suzuki coupling reaction, and then post-processed to obtain the purine compound.
[0010] Preferably, the amine compound in step (1) includes one or more of N,N-diethyl-p-phenylenediamine, N,N-dimethyl-p-phenylenediamine, p-phenylenediamine, 4-methoxyaniline, 4-methanesulfonamide-aniline, 4-(4-methylpiperazine)aniline, 4-(4-morpholino)aniline, 4-piperidineaniline, 1-Boc-4-(4-aminophenyl)piperazine, morpholine, and piperazine.
[0011] The base is triethylamine.
[0012] Preferably, the nucleophilic substitution reaction in step (1) and the Suzuki coupling reaction in step (2) are both carried out in an organic solvent, which includes one or more of pyridine, ethyl acetate and isopropanol.
[0013] Preferably, the nucleophilic substitution reaction in step (1) is carried out at a temperature of 70-100°C for 8 hours.
[0014] More preferably, the preparation method of 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine in step (1) includes the following steps: (1-1) Using xanthine (compound 1a) as a raw material, phosphorus oxychloride was subjected to a chlorination reaction to obtain intermediate 1b; (1-2) The intermediate 1b was subjected to a THP protection reaction with 3,4-dihydro-2H-pyran under trifluoroacetic acid conditions to introduce a protecting group, thereby obtaining intermediate 1c, namely the 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine.
[0015] More preferably, the chlorination reaction in step (1-1) is carried out at a temperature of 135°C for 5 hours.
[0016] More preferably, the temperature of the THP protection reaction in step (1-2) is 40°C and the time is 4h.
[0017] Preferably, the boric acid substrate in step (2) includes one or more of phenylboronic acid, substituted phenylboronic acid, or heteroarylboronic acid; The alkali is potassium carbonate; The palladium catalyst is either bis(tri-tert-butylphosphine)palladium or tetra(triphenylphosphine)palladium.
[0018] Preferably, the temperature of the Suzuki coupling reaction in step (2) is 100-120°C and the time is 8-12h.
[0019] Preferably, the post-processing in step (2) includes a protecting group removal process: The product of the Suzuki coupling reaction was dissolved in an organic solvent, and then concentrated hydrochloric acid was added dropwise to carry out acid-catalyzed hydrolysis at room temperature to complete the hydrochloric acid-catalyzed removal of the protecting group. or, The product of the Suzuki coupling reaction was mixed with sodium hydride in an organic solvent for deprotonation, followed by the dropwise addition of iodomethane for nucleophilic substitution. After the reaction was completed, the mixture was extracted, and hydrochloric acid was added dropwise to the resulting organic phase for catalytic hydrolysis to complete the removal of protecting groups.
[0020] More preferably, the preparation method includes the following steps: Synthesis Route 1: The commercially available compound 1a was reacted with phosphorus oxychloride to give intermediate 1b; intermediate 1b was reacted with 3,4-dihydro-2H-pyran under trifluoroacetic acid conditions to give intermediate 1c; intermediate 1c was reacted with different amines in the presence of triethylamine to give intermediate 1d; intermediate 1d was reacted with phenylboronic acid / heterocyclic boric acid under potassium carbonate and bis(tri-tert-butylphosphine)palladium catalysis to give intermediate 1e; intermediate 1e was reacted with hydrochloric acid to give target compound 1-24.
[0021] Synthesis Route 2: The commercially available compound 1a was reacted with phosphorus oxychloride to give intermediate 1b; intermediate 1b was reacted with 3,4-dihydro-2H-pyran under trifluoroacetic acid conditions to give intermediate 1c; intermediate 1c was reacted with different amines in the presence of triethylamine to give intermediate 1d; intermediate 1d was reacted with thiopheneboronic acid under potassium carbonate and tetra(triphenylphosphine)palladium catalysis to give intermediate 1e; intermediate 1e was reacted with hydrochloric acid to give target compounds 26-33 and 35.
[0022] Synthesis Route 3: The commercially available compound 1a was reacted with phosphorus oxychloride to give intermediate 1b; intermediate 1b was reacted with 3,4-dihydro-2H-pyran under trifluoroacetic acid conditions to give intermediate 1c; intermediate 1c was reacted with N,N-diethyl-p-phenylenediamine in the presence of triethylamine to give intermediate 1d; intermediate 1d was reacted with 3,4,5-trifluorophenylboronic acid / heterocyclic boric acid under potassium carbonate and bis(tri-tert-butylphosphine)palladium catalysis to give compound 25.
[0023] Synthesis Route 4: The commercially available compound 1a was reacted with phosphorus oxychloride to give intermediate 1b; intermediate 1b was reacted with 3,4-dihydro-2H-pyran under trifluoroacetic acid conditions to give intermediate 1c; intermediate 1c was reacted with morpholine in the presence of triethylamine to give intermediate 1d; intermediate 1d was reacted with thiopheneboronic acid under potassium carbonate and tetra(triphenylphosphine)palladium catalysis to give intermediate 34.
[0024] Synthesis Route 5: The commercially available compound 1a was reacted with phosphorus oxychloride to give intermediate 1b; intermediate 1b was reacted with 3,4-dihydro-2H-pyran under trifluoroacetic acid conditions to give intermediate 1c; intermediate 1c was reacted with different amines in the presence of triethylamine to give intermediate 1d; intermediate 1d was reacted with thiopheneboronic acid under potassium carbonate and tetra(triphenylphosphine)palladium catalysis to give intermediate 1e; intermediate 1e was reacted with iodomethane and treated with hydrochloric acid under the alkaline environment provided by sodium hydride to give target compound 36.
[0025] Application of a purine compound in the preparation of an antitumor drug targeting LSD1.
[0026] Compared with the prior art, the present invention has the following advantages and technical effects: This invention discloses a purine compound, its preparation method, and its applications. The compound is a purine compound with purine at the 2-position (R... 1 Introducing phenyl, substituted phenyl, five-membered heterocyclic or six-membered heterocyclic groups, and placing them at the 6-position (R 2 This invention introduces aniline, aromatic, or aliphatic amine groups to form purine derivatives with novel skeletal structures. The preparation method features mild reaction conditions, simple operation, and high reaction yield. Testing showed that the purine compounds obtained in this invention exhibit good reversible LSD1 inhibitory activity, providing a novel structural framework for developing highly effective LSD1-targeted antitumor drugs. When used to prepare LSD1-targeted antitumor drugs, the purine compounds provided by this invention exhibit good inhibitory activity against LSD1, demonstrating good drug development potential and providing a new direction for LSD1-targeted drug research and development. Attached Figure Description
[0027] The accompanying drawings, which form part of this invention, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings: Figure 1 The results showed that compound 30 promoted MHC-I expression in esophageal cancer cells and enhanced T cell-mediated cytotoxicity. Among them, (A) evaluates the effect of compound 30 on T cell-mediated killing of esophageal cancer cells by T cell cytotoxicity assay, and the ratio represents the ratio of T cells to tumor cells; (B) analyzes and quantifies the expression level of MHC-I (HLA-A / B / C) on the surface of KYSE410 and KYSE410 LSD1 KO cells treated with a specified concentration of compound 30 by flow cytometry; (C) verifies the promoting effect of compound 30 on STAT1 expression by Western blotting experiment; (D) verifyes the knockdown effect of STAT1 in esophageal cancer cells KYSE410 by Western blotting experiment; (E) analyzes the expression of MHC-I induced by compound 30 in STAT1 knockdown KYSE410 cells by flow cytometry. Figure 2 To evaluate the antitumor activity and preliminary in vivo tolerability of compound 30 in an immunocompetent C57BL / 6 mouse model of esophageal cancer syngeneic subcutaneous tumor; Among them, (A) are photographs of tumors removed from mice in the control group and treatment groups with different doses of compound 30; (B) are the tumor volume measurements of each group during compound 30 administration; (C) are the statistical analysis of tumor weight in each group after tumor resection; (D) are the body weight measurements of mice in each group during compound 30 administration; (E) are the histopathological assessment of the major organs of mice in each group by H&E staining, scale bar = 200 µm; (F) are the serum liver and kidney function indicators (AST, ALT, UA and Cre) levels of tumor-bearing mice in each treatment group. Figure 3 Evaluation of the reversible inhibition of LSD1 by compound 30. Detailed Implementation
[0028] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0029] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.
[0030] Unless otherwise specified, all raw materials used in the embodiments of this invention were purchased through commercial channels; Among them, the LSD1 protein was obtained in the laboratory by inserting the coding sequence of human LSD1 into the pET-28b expression vector, inducing it with 0.25mM IPTG (Meilun Biotechnology, China), and expressing it in Escherichia coli BL21(DE3) cells at 20℃. LSD1 substrate H3K4me2 was purchased from Jier Biochemical Co., Ltd.; The fluorescent dye Amplex was purchased from Parker Biosciences. Horseradish peroxidase (HRP) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. The human esophageal cancer KYSE410 cell line was purchased from the Cell Bank of the Chinese Academy of Sciences Type Culture Collection Committee. The LSD1 gene knockout KYSE410 LSD1 KO cell line was constructed by knocking out the LSD1 gene in human esophageal cancer cells KYSE410 using CRISPR-Cas9 technology. Anti-human HLA-A / B / C antibodies were purchased from Biolegend in the United States. Unless otherwise specified, room temperature or normal temperature in the embodiments of the present invention refers to 25±3℃.
[0031] Examples 1-24 describe the preparation of compounds 1-24, and the synthetic route is as follows: .
[0032] Example 1 A purine compound, with the structural formula of compound 1: Where: R 1 = R 2 = , X=NH.
[0033] A method for preparing a purine compound, comprising the following steps: (1) Add xanthine 1a (10 mmol) to 50 mL of pyridine and stir to dissolve. Add phosphorus oxychloride (20 mmol) dropwise to the reaction system and react at 135 °C for 5 hours. Monitor the reaction by thin-layer chromatography. When the reaction is complete, slowly pour the reaction solution into 50 mL of ice-water mixture and stir for 30 minutes. Extract the reaction mixture three times with 30 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate (" / " represents "and", the same below). Dry the obtained organic phase with anhydrous sodium sulfate, filter, remove the organic phase solvent by rotary evaporation, and separate by column chromatography to obtain intermediate 1b. (2) Intermediate 1b (10 mmol) was reacted with 3,4-dihydro-2 H15 mmol of pyran was added to 50 mL of ethyl acetate and stirred until dissolved. Then, 0.6 mmol of trifluoroacetic acid was added dropwise to the reaction system. The reaction was carried out at 40 °C for 4 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the organic solvent was removed by rotary evaporation at 35 °C. 45 mL of methanol was added to the resulting mixture and cooled to room temperature. The precipitated solid was separated from the methanol by filtration to obtain intermediate 1c. (3) Add intermediate 1c (10 mmol), N , N Diethyl-p-phenylenediamine (12 mmol) and triethylamine (12 mmol) were added sequentially to 50 mL of isopropanol. The mixture was heated and stirred at 70 °C for 8 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the resulting reaction solution was extracted three times with 50 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate. The resulting organic phase was dried over anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. The intermediate 1d was obtained by column chromatography.
[0034] (4) Intermediate 1d (1 mmol) and 4-(methanesulfonyl)phenylboronic acid (1.25 mmol) were added to 20 mL of 1,4-dioxane and water ( V 1,4-二氧六环 : V 水 In a mixed solvent of 4:1, potassium carbonate (1.75 mmol) and bis(tert-butylphosphine)palladium (0.05 mmol) were added sequentially. The mixture was heated and stirred at 100 °C for 8 hours under nitrogen protection. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the reaction solution was extracted three times with 10 mL of saturated sodium chloride aqueous solution / 10 mL of ethyl acetate. The resulting organic phase was dried over anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. The intermediate 1e was obtained by column chromatography. (5) Dissolve intermediate 1e (0.05 mmol) in 5 mL of dichloromethane and stir. Add 500 μL of concentrated hydrochloric acid dropwise to the reaction system and react at room temperature for 4 hours. Monitor the reaction by thin-layer chromatography. When the reaction is complete, collect the organic phase and remove the organic phase solvent by rotary evaporation. Add 3 mL of water to the remaining reaction solution and add saturated sodium bicarbonate solution dropwise until neutral. Filter to obtain the precipitated solid, which is compound 1. The yield is 87.1%.
[0035] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.27 (s, 1H), 8.60 (d, J = 8.4Hz, 2H), 8.10 (s, 1H), 7.80 (d,J = 9.0 Hz, 2H), 6.74 (d, J = 9.0 Hz, 3H), 3.34(q, J = 7.1 Hz, 4H), 3.26 (s, 3H), 1.11 (t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 156.57, 152.44, 150.08, 144.49, 143.61, 142.00, 128.49, 127.73,123.35, 119.41, 112.34, 44.35, 13.02. HRMS (ESI) calcd for C 22 H 24 N6O2S [M+ H] + ,437.1754; found: 437.1762. Example 2 A purine compound, with the structural formula of compound 2: ; Among them, R 1 = R 2 = , X=NH.
[0036] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of phenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 2 is finally obtained with a yield of 94.1%.
[0037] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.40 (s, 1H), 8.38 (d, J = 6.9Hz, 2H), 8.17 (s, 1H), 7.80 (d, J = 9.2 Hz, 2H), 7.50-7.45 (m, 2H), 7.44-7.41(m, 1H), 6.73 (d, J = 9.2 Hz, 2H), 3.33 (q, J = 7.0 Hz, 4H), 1.10 (t, J = 7.0 Hz, 6H).13 C NMR (100 MHz, DMSO- d 6) δ 157.09, 151.50, 143.97, 142.60, 139.80,129.71, 128.80, 127.98, 122.55, 112.67, 44.38, 13.01. HRMS (ESI) calcd forC 21 H 22 N6[M+ H] + , 359.1979; found: 359.1982. Example 3 A purine compound, with the structural formula of compound 3: ; Among them, R 1 = R 2 = , X=NH.
[0038] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-methylphenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 3 is finally obtained with a yield of 91.6%.
[0039] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.64 (s, 1H), 8.61 (s, 1H), 8.27 (d, J = 8.2 Hz, 2H), 8.22 (s, 1H), 7.80 (d, J = 9.0 Hz, 2H), 7.29 (d, J = 8.3Hz, 2H), 6.73 (d, J = 9.3 Hz, 2H), 3.33 (q, J = 7.0 Hz, 4H), 2.37 (s, 3H), 1.10(t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d6) δ 157.43, 153.94, 151.49, 144.04,142.28, 139.30, 137.01, 129.47, 127.99, 122.48, 117.97, 112.70, 44.40, 21.44,12.96. HRMS (ESI) calcd for C 22 H 24 N6[M+H] + , 373.2140; found: 373.2135. Example 4 A purine compound, with the structural formula of compound 4: ; Among them, R 1 = R 2 = , X=NH.
[0040] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-methoxyphenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 4 is finally obtained with a yield of 86.8%.
[0041] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 13.09 (d, J = 7.4 Hz, 1H), 9.42(s, 1H), 8.32 (d, J = 8.8 Hz, 2H), 8.19 (d, J = 8.8 Hz, 2H), 7.79 (d, J = 7.7 Hz, 2H), 7.04 (d, J = 8.9 Hz, 2H), 6.73-6.68 (m, 2H), 3.83 (s, 3H), 3.33-3.29 (m,4H), 1.10 (t, J = 7.1 Hz, 6H). 13 C NMR (100 MHz, DMSO-- d 6) δ 161.09, 131.84,129.59, 114.23, 102.98, 55.73, 12.87. HRMS (ESI) calcd for C 22 H24 N6O [M+H] + ,389.2090; found: 389.2085. Example 5 A purine compound, with the structural formula of compound 5: ; Among them, R 1 = R 2 = , X=NH.
[0042] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-methylthiophenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 5 is finally obtained with a yield of 92.6%.
[0043] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 12.63 (s, 1H), 8.36 (d, J = 8.4Hz, 2H), 7.88 (s, 1H), 7.72 (d, J = 6.0 Hz, 3H), 7.38 (s, 2H), 7.32 (d, J = 8.5Hz, 2H), 6.77 (d, J = 9.0 Hz, 2H), 3.37 (q, J = 7.1 Hz, 4H), 2.54 (s, 3H), 1.19(t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 158.56, 151.85, 144.41, 140.32,135.92, 128.45, 128.16, 125.66, 122.06, 112.59, 44.61, 15.38, 12.62. HRMS(ESI) calcd for C 22 H 24 N6S [M+H] + , 405.1856; found, 405.1870. Example 6 A purine compound, with the structural formula of compound 6: ; Among them, R 1 = R 2 = , X=NH.
[0044] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-fluorophenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 6 is finally obtained with a yield of 99.2%.
[0045] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 10.22 (s, 1H), 8.39 (s, 1H), 8.36-8.28 (m,, 2H), 8.16 (d, J = 8.6 Hz, 2H), 7.62 (d, J = 8.7 Hz, 2H), 7.27 (t, J = 8.6 Hz, 2H), 3.51 (q, J = 7.1 Hz, 4H), 1.00 (t, J = 7.0 Hz, 6H). 13 C NMR (100MHz, DMSO- d 6) δ 165.24, 162.78, 157.60, 152.58, 150.83, 141.27, 134.85,131.74, 130.55, 123.62, 121.34, 115.95, 53.29, 10.57. HRMS (ESI) calcd forC 21 H 21 FN6[M+H] + , 377.1844; found: 377.1888. Example 7 A purine compound, with the structural formula of compound 7: ; Among them, R 1 = R 2 = , X=NH.
[0046] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-chlorophenylboronic acid. The remaining process steps and parameters are the same as in Example 1. The compound is finally obtained with a yield of 82.4%.
[0047] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 13.29 (s, 1H), 9.60 (s, 1H), 8.48 (t, J = 8.1 Hz, 1H), 8.37 (d, J = 8.5 Hz, 1H), 8.31 (s, 1H), 7.88 (d, J = 8.4Hz, 1H), 7.81 (t, J = 9.5 Hz, 2H), 7.56 (t, J = 7.5 Hz, 2H), 6.78 (s, 1H), 3.62-3.36 (q, J = 7.2 Hz, 4H), 1.10 (t, J = 3.5 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ159.16, 151.62, 149.66, 141.89, 141.24, 140.77, 138.62, 136.99, 133.36,133.03, 132.73, 129.53, 129.08, 127.44, 124.11, 121.11, 52.91, 10.53. HRMS(ESI) calcd for C 21 H 21 ClN6[M+H] + , 393.1589; found: 393.1592. Example 8 A purine compound, with the structural formula of compound 8: ; Among them, R 1 = R 2 = , X=NH.
[0048] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-trifluoromethylphenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 8 is finally obtained with a yield of 90.1%.
[0049] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 13.19 (s, 1H), 9.64 (s, 1H), 8.69 (s, 1H), 8.63 (d, J = 8.4 Hz, 2H), 8.29 (s, 1H), 7.81 (d, J = 6.8 Hz, 1H), 7.75 (t, J = 7.5 Hz, 3H), 6.73 (m, 1H), 3.34 (q, J = 7.0 Hz, 4H) 1.11 (t, J = 7.0Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 157.37, 152.40, 150.31, 141.83, 139.24,132.65, 131.91, 130.61, 130.13, 129.81, 127.24, 126.10, 124.51, 123.92,123.39, 121.66, 52.90, 10.50. HRMS (ESI) calcd for C 22 H 21 F3N6[M+H] + , 427.1853;found: 427.1845. Example 9 A purine compound, with the structural formula of compound 9: ; Among them, R 1 = R 2 = , X=NH.
[0050] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-nitrophenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 9 is finally obtained with a yield of 97.3%.
[0051] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.58 (s, 1H), 8.58 (d, J = 9.0Hz, 2H), 8.36 (d, J = 9.0 Hz, 2H), 8.29 (s, 2H), 7.74 (d, J = 9.0 Hz, 2H), 6.74(d, J = 9.2 Hz, 2H), 3.36 (m, 4H), 1.12 (t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 155.81, 148.59, 145.15, 129.17, 124.35, 51.70, 10.61. HRMS (ESI)calcd for C 21 H 21 N7O2[M+H] + , 404.1835; found: 404.1830. Example 10 A purine compound, with the structural formula of compound 10: ; Among them, R 1 = R 2 = , X=NH.
[0052] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-hydroxyphenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 10 is finally obtained with a yield of 95.3%.
[0053] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.39 (s, 1H), 8.21 (d, J = 8.7Hz, 2H), 8.12 (s, 1H), 7.79 (d, J = 9.2 Hz, 2H), 6.86 (d, J= 8.7 Hz, 2H), 6.73(d, J = 9.2 Hz, 2H), 3.32 (q, J = 7.0 Hz, 4H), 1.10 (t, J = 7.0 Hz, 6H). 13 C NMR (100MHz, DMSO- d 6) δ 159.10, 157.29, 153.44, 150.83, 143.41, 129.93, 129.12,121.86, 116.61, 114.85, 112.39, 112.02, 43.82, 12.28. HRMS (ESI) calcd forC 21 H 22 N6O[M+H] + , 375.1933; found: 375.1925. Example 11 A purine compound, with the structural formula of compound 11: ; Among them, R 1 = R 2 = , X=NH.
[0054] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-cyanophenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 11 is finally obtained with a yield of 86.8%.
[0055] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.13 (s, 1H), 8.52 (d, J = 8.4Hz, 2H), 8.03 (s, 1H), 7.71 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 9.0 Hz, 2H), 6.2(d, J = 9.2 Hz, 2H), 3.3 (q, J = 7.0 Hz, 4H), 1.10 (t, J = 7.0 Hz, 6H). 13C NMR (100MHz, DMSO- d 6) δ 151.27, 144.52, 143.98, 132.87, 128.44, 122.53, 119.68,112.74, 111.52, 44.42, 13.03. HRMS (ESI) calcd for C 22 H 21 N7[M+H] + , 384.1936;found: 384.1934. Example 12 A purine compound, with the structural formula of compound 12: ; Among them, R 1 = R 2 = , X=NH.
[0056] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-piperazinylphenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 12 is finally obtained with a yield of 73.7%.
[0057] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.33 (s, 1H), 8.22 (d, J = 8.9Hz, 2H), 8.15 (s, 1H), 7.79 (d, J = 8.5 Hz, 2H), 6.99 (d, J = 9.0 Hz, 2H), 6.72(d, J = 9.2 Hz, 2H), 3.34 (q, J = 7.0 Hz, 4H), 3.16 (t, J = 5.0 Hz, 4H), 2.85 (t, J =5.1 Hz, 4H), 1.10 (t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d6) δ 158.39,152.82, 144.08, 129.34, 129.12, 122.70, 114.75, 112.56, 48.88, 45.82, 44.38,13.02. HRMS (ESI) calcd for C 25 H 30 N8[M+H] + , 443.2666; found: 443.2661. Example 13 A purine compound, with the structural formula of compound 13: ; Among them, R 1 = R 2 = , X=NH.
[0058] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-piperazine methylphenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 13 is finally obtained with a yield of 96.7%.
[0059] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 13.11 (s, 1H), 11.36 (s, 1H), 9.04 (s, 1H), 8.27 (d, J = 9.0 Hz, 4H), 7.92 (d, J = 6.9 Hz, 2H), 7.20 (d, J = 9.0Hz, 2H), 4.08 (d, J = 13.6 Hz, 2H), 3.57-3.50 (m, 4H), 3.47 (m, 2H), 3.30(t, J =12.4 Hz, 2H), 3.15 (d, J = 11.2 Hz, 2H), 2.80 (d, J = 4.8 Hz, 3H), 1.10 (t, J = 7.2Hz, 6H). 13 C NMR (100 MHz, DMSO- d6) δ 157.22, 151.62, 150.74, 143.35, 129.29,128.39, 121.90, 114.46, 114.08, 111.96, 54.50, 47.45, 43.85, 12.63, 9.30.HRMS (ESI) calcd for C 26 H 32 N8[M+H] + , 457.2828; found: 457.2821. Example 14 A purine compound, with the structural formula of compound 14: ; Among them, R 1 = R 2 = , X=NH.
[0060] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 4-morpholinophenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 14 is finally obtained with a yield of 90.3%.
[0061] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.37 (s, 1H), 8.25 (d, J = 8.9Hz, 2H), 8.13 (s, 1H), 7.80 (d, J = 9.2 Hz, 2H), 7.02 (d, J = 9.2 Hz, 2H), 6.72(d, J = 9.2 Hz, 2H), 3.76-3.74 (m, 4H), 3.33 (q, J = 7.0 Hz, 4H), 3.20(t, J = 5.0Hz, 4H), 1.10 (t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d6) δ 152.42, 144.04,129.10, 122.65, 114.64, 112.52, 66.56, 48.31, 44.38, 13.03. HRMS (ESI) calcdfor C 25 H 29 N7O[M+H] + , 444.2506; found: 444.2510. Example 15 A purine compound, with the structural formula of compound 15: ; Among them, R 1 = R 2 = , X=NH.
[0062] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 2-furanboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 15 is finally obtained with a yield of 96.1%.
[0063] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 13.06 (s, 1H), 9.49 (s, 1H), 8.21 (s, 1H), 7.83-7.80 (d, J = 9.3 Hz, 2H), 7.11-7.10 (d, J = 3.4 Hz, 1H), 6.72-6.69 (d, J = 9.2 Hz, 2H), 6.65 (s, 1H), 3.35 (m, 2H), 3.32-3.30 (m, 2H), 1.11-1.09 (t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 154.16, 151.19, 144.36,143.88, 129.81, 112.79, 111.04, 44.42, 12.97. HRMS (ESI) calcd for C 19 H 20 N6O[M+H] +, 349.1777; found: 349.1770. Example 16 A purine compound, with the structural formula of compound 16: ; Among them, R 1 = R 2 = , X=NH.
[0064] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 2-thiopheneboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 16 is finally obtained with a yield of 91.1%.
[0065] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 13.29-12.99 (m, 1H), 10.03-9.35 (m, 1H), 8.21 (s, 1H), 7.82 (s, 2H), 7.68-7.46 (m, 1H), 7.22-7.11 (m, 1H), 6.72 (s, 2H), 3.36-3.26 (m, 4H), 1.19-1.00 (m, 6H). 13 C NMR (100 MHz, DMSO- d 6)δ 154.30, 144.93, 128.54, 127.84, 126.87, 122.08, 113.16, 112.15, 43.74,12.57. HRMS (ESI) calcd for C 19 H 20 N6S[M+H] + , 365.1548; found: 365.1552. Example 17 A purine compound, with the structural formula of compound 17: ; Among them, R 1 = R 2 = , X=NH.
[0066] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 1-methyl-1H-pyrazole-5-boronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 17 is finally obtained with a yield of 97.3%.
[0067] The structure is characterized as: brown solid, melting point: 279.1-281.0 ℃, yield: 97.3%. 1 H NMR (400 MHz, DMSO- d 6) δ 9.34 (s, 1H), 8.17 (s, 1H), 8.10 (s, 1H), 7.94 (s, 1H), 7.82 (d, J = 9.2 Hz, 2H), 6.73 (d, J = 9.2 Hz, 2H), 3.92 (s, 3H), 3.32(q, J = 7.0 Hz, 4H), 1.10 (t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 154.45,151.55, 143.82, 141.06, 138.87, 131.22, 129.80, 124.56, 122.23, 117.26,112.75, 44.40, 13.02. HRMS (ESI) calcd for C 19 H 22 N8[M+H] + , 363.2040; found:363.2042. Example 18 A purine compound, with the structural formula of compound 18: ; Among them, R 1 = R 2 = , X=NH.
[0068] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of pyridine-3-boronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 18 is finally obtained with a yield of 45.1%.
[0069] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.61 (s, 1H), 9.54 (d, J = 2.4Hz, 1H), 8.71-8.68 (m, 1H), 8.68-8.64 (m, 1H), 8.32 (s, 1H), 7.80 (d, J = 9.2Hz, 2H), 7.62-7.54 (m, 1H), 6.79 (d, J = 9.2 Hz, 2H), 3.44-3.40 (d, J = 7.2 Hz, 4H), 1.16 (t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 156.10, 150.74,149.40, 144.35, 135.25, 134.65, 128.71, 124.13, 123.17, 112.40, 44.34, 13.01.HRMS (ESI) calcd for C 20 H 21 N7[M+H] + , 360.1931; found: 360.1936. Example 19 A purine compound, with the structural formula of compound 19: ; Among them, R 1 = R 2 = , X=NH.
[0070] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 5-pyrimidineboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 19 is finally obtained with a yield of 13.3%.
[0071] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d6) δ 13.24 (s, 1H), 9.68 (s, 1H), 9.50 (s, 2H), 9.22 (s, 1H), 8.25 (s, 1H), 7.67 (d, J = 9.0 Hz, 2H), 6.69 (d, J =9.2 Hz, 2H), 3.35-3.33 (m, 4H), 1.06 (t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 159.22, 156.18, 154.00, 152.44, 151.10, 144.56, 140.88, 132.32, 128.32,123.48, 119.29, 112.34, 44.35, 12.99. HRMS (ESI) calcd for C 19 H 20 N8[M+H] + ,361.1884; found: 361.1887. Example 20 A purine compound, with the structural formula of compound 20: ; Among them, R 1 = R 2 = , X=NH.
[0072] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of benzo-1,4-dioxane-6-boronic acid. The remaining process steps and parameters are the same as in Example 1. Compound 20 is finally obtained with a yield of 93.6%.
[0073] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 13.01 (s, 1H), 9.41 (s, 1H), 8.17 (s, 1H), 7.97-7.56 (m, 4H), 6.94 (s, 1H), 6.71 (s, 2H), 4.30 (s, 4H), 3.34 (s, 4H), 1.10 (s, 6H). 13 C NMR (100 MHz, DMSO-d 6) δ 157.54, 145.38,143.56, 139.95, 132.78, 129.09, 123.02, 121.33, 117.41, 116.81, 112.42,64.80, 44.34, 12.99. HRMS (ESI) calcd for C 23 H 24 N6O2[M+H] + , 417.2034; found:417.2037. Example 21 A purine compound, with the structural formula of compound 21: ; Among them, R 1 = R 2 = , X=NH.
[0074] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 3-F-4-methyl-phenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 21 is finally obtained with a yield of 90.8%.
[0075] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.48 (s, 1H), 8.20 (s, 1H), 8.10 (d, J = 7.9 Hz, 1H), 7.99 (d, J = 11.8 Hz, 2H), 7.74 (d, J = 9.0 Hz, 2H), 7.39(t, J = 8.0 Hz, 1H), 6.72 (d, J = 9.0 Hz, 2H), 3.34 (q, J = 7.0 Hz, 4H), 2.30 (s,3H), 1.10 (t, J = 7.0 Hz, 6H). 13 C NMR (100 MHz, DMSO- d6) δ 162.47, 160.07,156.25, 153.56, 151.56, 144.15, 142.07, 139.87, 132.08, 129.12, 125.93,123.62, 122.94, 114.09, 112.48, 44.38, 14.71, 12.98. Example 22 A purine compound, with the structural formula of compound 22: ; Among them, R 1 = R 2 = , X=NH.
[0076] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 3-F-4-methoxy-phenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 22 is finally obtained with a yield of 45.1%.
[0077] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 10.31 (s, 1H), 8.49 (s, 1H), 8.20 (d, J = 9.2 Hz, 2H), 8.15 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 12.8 Hz, 1H), 7.70(d, J = 9.0 Hz, 2H), 7.29 (t, J = 8.8 Hz, 1H), 3.91 (s, 3H), 3.58 (q, J = 7.1 Hz, 4H), 1.07 (t, J = 7.2 Hz, 6H). 13 C NMR (100 MHz, DMSO- d6) δ 157.95, 153.05,152.04, 150.63, 150.05, 149.69, 149.59, 141.38, 132.55, 131.05, 125.06,123.97, 121.24, 115.42, 115.22, 114.27, 56.71, 52.89, 10.54. HRMS (ESI) calcdfor C 22 H 23 FN6O[M+H] + , 407.1990; found: 407.1993. Example 23 A purine compound, with the structural formula of compound 23: ; Among them, R 1 = R 2 = , X=NH.
[0078] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 3-F-4-cyano-phenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 23 is finally obtained with a yield of 37.5%.
[0079] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.51 (s, 1H), 8.28 (d, J = 9.6Hz, 1H), 8.21 (s, 1H), 8.18 (d, J = 11.2 Hz, 1H), 7.99 (d, J = 6.9 Hz, 1H), 7.64 (d, J = 9.0 Hz, 2H), 6.67 (d, J = 9.0 Hz, 2H), 3.32-3.26 (m, 4H), 1.06 (t, J = 7.0Hz, 6H). 13 C NMR (100 MHz, DMSO- d6) δ 161.91, 154.26, 151.61, 147.24, 144.37,128.72, 123.25, 118.90, 114.82, 113.16, 111.74, 100.70, 44.39, 13.11. HRMS(ESI) calcd for C 22 H 20 FN7[M+H] + , 402.1837; found: 402.1836. Example 24 A purine compound, with the structural formula of compound 24: ; Among them, R 1 = R 2 = , X=NH.
[0080] A method for preparing a purine compound differs from Example 1 only in that 4-(methanesulfonyl)phenylboronic acid in step (4) is replaced with an equimolar amount of 3,4,5-trimethoxyphenylboronic acid. The remaining process steps and parameters are the same as in Example 1, and compound 24 is finally obtained with a yield of 37.5%.
[0081] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 10.30 (s, 1H), 8.41 (s, 1H), 8.16 (d, J = 8.9 Hz, 2H), 7.74-7.61 (m, 4H), 3.87 (s, 9H), 3.59-3.56 (d, J = 7.7Hz, 4H), 1.05 (t, J = 7.2 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 157.45, 153.28,152.74, 150.74, 141.79, 141.06, 139.61, 133.68, 132.08, 123.25, 122.46,117.01, 105.07, 60.73, 56.15, 53.17, 10.54. HRMS (ESI) calcd for C 24 H 28 N6O3[M+H]+ , 446.2296; found: 446.2297. Example 25 describes the preparation of compound 25, using the following synthetic route: Example 25 A purine compound, with the structural formula of compound 25: ; Among them, R 1 = R 2 = , X=NH.
[0082] A method for preparing a purine compound, comprising the following steps: (1) Add xanthine 1a (10 mmol) to 50 mL of pyridine and stir to dissolve. Add phosphorus oxychloride (20 mmol) dropwise to the reaction system and react at 135 °C for 5 hours. Monitor the reaction by thin-layer chromatography. When the reaction is complete, slowly pour the reaction solution into 50 mL of ice-water mixture and stir for 30 minutes. Extract the reaction mixture three times with 30 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate as the extraction solution. Dry the obtained organic phase with anhydrous sodium sulfate, filter, remove the organic phase solvent by rotary evaporation, and separate by column chromatography to obtain intermediate 1b. (2) Intermediate 1b (10 mmol) was reacted with 3,4-dihydro-2 H 15 mmol of pyran was added to 50 mL of ethyl acetate and stirred until dissolved. Then, 0.6 mmol of trifluoroacetic acid was added dropwise to the reaction system. The reaction was carried out at 40 °C for 4 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the organic solvent was removed by rotary evaporation at 35 °C. 45 mL of methanol was added to the resulting mixture and cooled to room temperature. The precipitated solid was separated from the methanol by filtration to obtain intermediate 1c. (3) Add intermediate 1c (10 mmol), N , N Diethyl-p-phenylenediamine (12 mmol) and triethylamine (12 mmol) were added sequentially to 50 mL of isopropanol. The mixture was heated and stirred at 70 °C for 8 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the resulting reaction solution was extracted three times with 50 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate. The resulting organic phase was dried over anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. The intermediate 1d was obtained by column chromatography.
[0083] (4) Intermediate 1d (1 mmol) and 3,4,5-trifluorophenylboronic acid (1.25 mmol) were added to 20 mL of 1,4-dioxane and water ( V 1,4-二氧六环 : V 水 In a mixed solvent of 4:1, potassium carbonate (1.75 mmol) and bis(tert-butylphosphine)palladium (0.05 mmol) were added sequentially. The mixture was heated and stirred at 100 °C for 6 hours under nitrogen protection. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the reaction solution was extracted three times with 10 mL of saturated sodium chloride aqueous solution / 10 mL of ethyl acetate. The resulting organic phase was dried over anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. Compound 25 was obtained by column chromatography with a yield of 30.1%.
[0084] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 10.26 (s, 1H), 8.38 (s, 1H), 8.14 (d, J = 9.0 Hz, 2H), 8.08-7.99 (m, 2H), 7.67 (d, J = 8.9 Hz, 2H), 3.59-3.57 (d, J = 7.4 Hz, 4H), 1.07 (t, J = 7.2 Hz, 6H). 13 C NMR (100 MHz, DMSO- d 6) δ 152.69,151.10, 142.39, 141.13, 131.99, 123.48, 121.77, 118.09, 112.05, 53.18, 10.58.HRMS (ESI) calcd for C 21 H 19 F3N6[M+H] + , 413.1696; found: 413.1701. Examples 26-34 describe the preparation of compounds 26-33 and 35, using the following synthetic routes: Example 26 A purine compound, with the structural formula of compound 26: ; Among them, R 1 = R2 = , X=NH.
[0085] A method for preparing a purine compound, comprising the following steps: (1) Add xanthine 1a (10 mmol) to 50 mL of pyridine and stir to dissolve. Add phosphorus oxychloride (20 mmol) dropwise to the reaction system and react at 135 °C for 5 hours. Monitor the reaction by thin-layer chromatography. When the reaction is complete, slowly pour the reaction solution into 50 mL of ice-water mixture and stir for 30 minutes. Extract the reaction mixture three times with 30 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate as the extraction solution. Dry the obtained organic phase with anhydrous sodium sulfate, filter, remove the organic phase solvent by rotary evaporation, and separate by column chromatography to obtain intermediate 1b. (2) Intermediate 1b (10 mmol) was reacted with 3,4-dihydro-2 H 15 mmol of pyran was added to 50 mL of ethyl acetate and stirred until dissolved. Then, 0.6 mmol of trifluoroacetic acid was added dropwise to the reaction system. The reaction was carried out at 40 °C for 4 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the organic solvent was removed by rotary evaporation at 35 °C. 45 mL of methanol was added to the resulting mixture and cooled to room temperature. The precipitated solid was separated from the methanol by filtration to obtain intermediate 1c. (3) Intermediate 1c (10 mmol), p-phenylenediamine (12 mmol), and triethylamine (12 mmol) were added sequentially to 50 mL of isopropanol. The mixture was heated and stirred at 70 °C for 8 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the resulting reaction solution was extracted three times with 50 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate. The resulting organic phase was dried with anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. Intermediate 1d was obtained by column chromatography.
[0086] (4) Intermediate 1d (1 mmol) and 2-thiopheneboronic acid (1.25 mmol) were added to 20 mL of N,N-dimethylformamide solvent, followed by potassium carbonate (1.75 mmol) and tetrakis(triphenylphosphine)palladium (0.05 mmol). The mixture was heated and stirred at 100 °C for 10 hours under nitrogen protection. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the reaction solution was extracted three times with 10 mL of saturated sodium chloride aqueous solution / 10 mL of dichloromethane. The resulting organic phase was dried with anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. Intermediate 1e was obtained by column chromatography. (5) Dissolve intermediate 1e (0.05 mmol) in 5 mL of dichloromethane and stir. Add 500 μL of concentrated hydrochloric acid dropwise to the reaction system and react at room temperature for 4 hours. Monitor the reaction by thin-layer chromatography. When the reaction is complete, collect the organic phase and remove the organic phase solvent by rotary evaporation. Add 3 mL of water to the remaining reaction solution and add saturated sodium bicarbonate solution dropwise until neutral. Filter to obtain the precipitated solid, which is compound 26, with a yield of 96.1%.
[0087] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.50 (s, 1H), 8.16 (s, 1H), 7.77 (d, J = 5.0 Hz, 1H), 7.65 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 5.0 Hz, 1H), 7.18-7.12 (m, 1H), 6.61 (d, J = 8.8 Hz, 2H), 4.87 (s, 2H). 13 C NMR (100 MHz, DMSO- d 6)δ 154.36, 151.09, 145.91, 144.72, 141.77, 129.68, 128.86, 126.97, 122.43,114.31. HRMS (ESI) calcd for C 15 H 12 N6S[M+H] + , 309.0917; found: 309.0920. Example 27 A purine compound, with the structural formula of compound 27: ; Among them, R 1 = R 2 = , X=NH.
[0088] A method for preparing a purine compound, differing from Example 26 only in that p-phenylenediamine in step (3) is replaced with an equimolar amount of... N , N -Dimethyl-p-phenylenediamine, the remaining process steps and parameters are the same as in Example 26, and finally compound 27 is obtained with a yield of 91.1%.
[0089] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.62 (s, 1H), 8.20 (s, 1H), 7.87 (d, J = 9.0 Hz, 2H), 7.80 (d, J = 3.8 Hz, 1H), 7.61 (d, J = 4.9 Hz, 1H), 7.19-7.13 (m, 1H), 6.78 (d, J = 9.2 Hz, 2H), 2.88 (s, 6H). 13 C NMR (100 MHz, DMSO- d 6)δ 154.67, 152.76, 151.28, 147.14, 145.63, 141.07, 130.39, 129.12, 128.59,127.24, 122.08, 117.43, 113.22, 41.19. HRMS (ESI) calcd for C 17 H 16 N6S[M+H] + ,337.1230; found: 337.1232. Example 28 A purine compound, with the structural formula of compound 28: ; Among them, R 1 = R 2 = , X=NH.
[0090] A method for preparing a purine compound differs from Example 26 only in that p-phenylenediamine in step (3) is replaced with an equimolar amount of 1-Boc-4-(4-aminophenyl)piperazine. All other process steps and parameters are the same as in Example 26, and compound 28 is finally obtained with a yield of 93.4%.
[0091] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 11.33 (s, 1H), 9.62 (s, 2H), 9.36 (s, 1H), 8.03 (d, J = 3.8 Hz, 1H), 7.97 (d, J= 9.0 Hz, 2H), 7.84 (d, J = 5.0Hz, 1H), 7.26 (t, J = 4.3 Hz, 1H), 7.21 (d, J = 5.8 Hz, 2H), 3.49 (s, 4H), 3.29(s, 4H). 13 C NMR (100 MHz, DMSO- d 6) δ 155.96, 149.71, 148.61, 146.35, 142.09,132.37, 131.95, 129.73, 129.28, 121.67, 117.39, 109.66, 46.61, 42.91. HRMS(ESI) calcd for C 19 H 20 ClN7S[M+H] + , 414.1652; found: 414.1268. Example 29 A purine compound, with the structural formula of compound 29: ; Among them, R 1 = R 2 = , X=NH.
[0092] A method for preparing a purine compound differs from Example 26 only in that p-phenylenediamine in step (3) is replaced with an equimolar amount of 4-(4-methylpiperazine)aniline. All other process steps and parameters are the same as in Example 26, and compound 29 is finally obtained with a yield of 93.4%.
[0093] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.64 (s, 1H), 8.21 (s, 1H), 7.90 (d, J = 9.2 Hz, 2H), 7.81 (d, J = 4.9 Hz, 1H), 7.62 (d, J = 5.1 Hz, 1H), 7.20-7.14 (m, 1H), 6.97 (d, J = 9.2 Hz, 2H), 3.15-3.08 (m, 4H), 2.46 (t, J= 5.0 Hz, 4H), 2.22 (s, 3H). 13 C NMR (100 MHz, DMSO- d 6) δ 154.80, 151.40, 147.26, 145.35,140.74, 132.32, 129.29, 128.67, 127.44, 121.85, 116.11, 55.21, 49.17, 46.29.HRMS (ESI) calcd for C 20 H 21 N7S[M+H] + , 392.1652; found: 392.1657. Example 30 A purine compound, with the structural formula of compound 30: ; Among them, R 1 = R 2 = , X=NH.
[0094] A method for preparing a purine compound differs from Example 26 only in that p-phenylenediamine in step (3) is replaced with an equimolar amount of 4-(4-morpholino)aniline. All other process steps and parameters are the same as in Example 26, and compound 30 is finally obtained with a yield of 90.1%.
[0095] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.62 (s, 1H, -NH-), 8.18 (s,1H, -C5H2N4-), 7.93 (d, J = 9.2 Hz, 2H, Ar-H), 7.80 (d, J = 3.5 Hz, 1H, -C4H3S),7.61 (d, J = 6.4 Hz, 1H, -C4H3S), 7.19-7.13 (m, 1H, -C4H3S), 6.98 (d, J = 9.2 Hz, 2H, Ar-H), 3.79-3.72 (m, 4H, -C4H8NO), 3.12-3.05 (m, 4H, -C4H8NO). 13 C NMR (100MHz, DMSO- d6) δ 154.20, 151.17, 147.06, 145.80, 142.22, 133.01, 128.94,128.58, 127.04, 121.63, 115.91, 66.72, 49.65. HRMS (ESI) calcd for C 19 H 18 N6OS[M+H] + , 379.1336; found: 379.1339. Example 31 A purine compound, with the structural formula of compound 31: ; Among them, R 1 = R 2 = , X=NH.
[0096] A method for preparing a purine compound differs from that in Example 26 only in that p-phenylenediamine in step (3) is replaced with an equimolar amount of 4-piperidineaniline. All other process steps and parameters are the same as in Example 26, and compound 31 is finally obtained with a yield of 93.6%.
[0097] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.61 (s, 1H), 8.15 (s, 1H), 7.84 (d, J = 9.2 Hz, 2H), 7.77-7.74 (m, 1H), 7.58-7.56 (m, 1H), 7.14-7.10 (m,1H), 6.95-6.87 (m, 2H), 3.09-3.02 (m, 4H), 1.64-1.56 (p, J = 5.4 Hz, 4H), 1.52-1.45 (q, J = 5.4 Hz, 2H). 13 C NMR (100 MHz, DMSO- d 6) δ 156.45, 154.35, 151.11,147.91, 142.44, 139.33, 137.62, 127.73, 122.55, 115.92, 95.95, 50.97, 24.72,16.36.HRMS (ESI) calcd for C 20 H20 N6S[M+H] + , 377.1543; found: 377.1548. Example 32 A purine compound, with the structural formula of compound 32: ; Among them, R 1 = R 2 = , X=NH.
[0098] A method for preparing a purine compound differs from Example 26 only in that p-phenylenediamine in step (3) is replaced with an equimolar amount of 4-methanesulfonamide aniline. All other process steps and parameters are the same as in Example 26, and compound 32 is finally obtained with a yield of 84.8%.
[0099] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.88 (s, 1H), 8.27 (s, 1H), 8.05 (d, J = 9.0 Hz, 2H), 7.83 (d, J = 3.6 Hz, 1H), 7.65 (d, J = 5.0 Hz, 1H), 7.24(d, J = 9.0 Hz, 2H), 7.21-7.16 (m, 1H), 2.98 (s, 3H). 13 C NMR (100 MHz, DMSO- d 6)δ 154.69, 145.15, 137.19, 133.14, 129.48, 128.75, 127.58, 121.80, 121.53.HRMS (ESI) calcd for C 16 H 15 N6O2S2[M+H] + , 387.0692; found: 387.0697. Example 33 A purine compound, with the structural formula of compound 33: ; Among them, R 1 = R 2 = , X=NH.
[0100] A method for preparing a purine compound differs from Example 26 only in that p-phenylenediamine in step (3) is replaced with an equimolar amount of 4-methoxyaniline. All other process steps and parameters are the same as in Example 26, and compound 33 is finally obtained with a yield of 73.5%.
[0101] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 9.42 (s, 1H), 7.99 (d, J = 9.2Hz, 1H), 7.75 (d, J = 3.1 Hz, 1H), 7.53 (d, J = 5.1 Hz, 1H), 7.17-7.10 (m, 1H), 6.93 (d, J = 9.2 Hz, 1H), 3.76 (s, 2H). 13 C NMR (100 MHz, DMSO- d 6) δ 155.45,154.84, 153.20, 150.93, 146.41, 134.25, 129.21, 127.78, 126.47, 121.66,118.93, 114.89, 113.48, 55.20. HRMS (ESI) calcd for C 16 H 13 N5OS[M+H] + , 324.0914;found: 324.0917. Example 34 A purine compound, with the structural formula of compound 35: ; Among them, R 1 = R 2 = X = - (i.e., R) 2 Choose a direct C-link to the mother core.
[0102] A method for preparing a purine compound differs from Example 26 only in that p-phenylenediamine in step (3) is replaced with an equimolar amount of piperazine. All other process steps and parameters are the same as in Example 26, ultimately yielding compound 35 with a yield of 73.5%. The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d6) δ 7.94 (s, 1H), 7.74 (s, 1H), 7.52 (s, 1H), 7.10 (d, J = 8.2 Hz, 1H), 4.18 (s, 4H), 2.81 (s, 4H). 13 C NMR (100 MHz, DMSO- d 6) δ 153.01, 128.27, 127.92, 126.23, 121.94, 119.53, 95.06, 46.43,26.77. HRMS (ESI) calcd for C 13 H 14 N6S[M+H] + , 287.1073; found: 287.1075. Example 35 describes the preparation of compound 34, using the following synthetic route: Example 35 A purine compound, with the structural formula of compound 34: ; Among them, R 1 = R 2 = X = - (i.e., R) 2 Choose a direct C-link to the mother core.
[0103] A method for preparing a purine compound, comprising the following steps: (1) Add xanthine 1a (10 mmol) to 50 mL of pyridine and stir to dissolve. Add phosphorus oxychloride (20 mmol) dropwise to the reaction system and react at 135 °C for 5 hours. Monitor the reaction by thin-layer chromatography. When the reaction is complete, slowly pour the reaction solution into 50 mL of ice-water mixture and stir for 30 minutes. Extract the reaction mixture three times with 30 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate as the extraction solution. Dry the obtained organic phase with anhydrous sodium sulfate, filter, remove the organic phase solvent by rotary evaporation, and separate by column chromatography to obtain intermediate 1b. (2) Intermediate 1b (10 mmol) was reacted with 3,4-dihydro-2 H15 mmol of pyran was added to 50 mL of ethyl acetate and stirred until dissolved. Then, 0.6 mmol of trifluoroacetic acid was added dropwise to the reaction system. The reaction was carried out at 40 °C for 4 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the organic solvent was removed by rotary evaporation at 35 °C. 45 mL of methanol was added to the resulting mixture and cooled to room temperature. The precipitated solid was separated from the methanol by filtration to obtain intermediate 1c. (3) Intermediate 1c (10 mmol), morpholine (12 mmol), and triethylamine (12 mmol) were added sequentially to 50 mL of isopropanol. The mixture was heated and stirred at 70 °C for 8 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the resulting reaction solution was extracted three times with 50 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate. The resulting organic phase was dried with anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. Intermediate 1d was obtained by column chromatography.
[0104] (4) Intermediate 1d (1 mmol) and 2-thiopheneboronic acid (1.25 mmol) were added to 20 mL of N,N-dimethylformamide solvent, followed by potassium carbonate (1.75 mmol) and tetrakis(triphenylphosphine)palladium (0.05 mmol). The mixture was heated and stirred at 100 °C for 10 hours under nitrogen protection. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the reaction solution was extracted three times with 10 mL of saturated sodium chloride aqueous solution / 10 mL of dichloromethane. The resulting organic phase was dried with anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. Compound 34 was obtained by column chromatography with a yield of 7.3%.
[0105] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 13.10 (s, 1H), 8.13 (s, 1H), 7.81 (s, 1H), 7.60 (s, 1H), 7.14 (s, 1H), 4.26 (s, 4H), 3.76 (s, 4H). 13 C NMR (100 MHz, DMSO-) d 6) δ 154.54, 153.27, 152.73, 144.97, 139.16, 132.07, 131.97,129.39, 129.27, 128.58, 127.66, 118.21, 66.74, 45.50. HRMS (ESI) calcd forC 13 H 13 N5OS[M+H] +, 288.0914; found: 288.0918. Example 36 describes the preparation of compound 36, and the synthetic route is as follows: Example 36 A purine compound, with the structural formula of compound 36: ; Among them, R 1 = R 2 = , X=NMe.
[0106] A method for preparing a purine compound, comprising the following steps: (1) Add xanthine 1a (10 mmol) to 50 mL of pyridine and stir to dissolve. Add phosphorus oxychloride (20 mmol) dropwise to the reaction system and react at 135 °C for 5 hours. Monitor the reaction by thin-layer chromatography. When the reaction is complete, slowly pour the reaction solution into 50 mL of ice-water mixture and stir for 30 minutes. Extract the reaction mixture three times with 30 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate as the extraction solution. Dry the obtained organic phase with anhydrous sodium sulfate, filter, remove the organic phase solvent by rotary evaporation, and separate by column chromatography to obtain intermediate 1b. (2) Intermediate 1b (10 mmol) was reacted with 3,4-dihydro-2 H 15 mmol of pyran was added to 50 mL of ethyl acetate and stirred until dissolved. Then, 0.6 mmol of trifluoroacetic acid was added dropwise to the reaction system. The reaction was carried out at 40 °C for 4 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the organic solvent was removed by rotary evaporation at 35 °C. 45 mL of methanol was added to the resulting mixture and cooled to room temperature. The precipitated solid was separated from the methanol by filtration to obtain intermediate 1c. (3) Intermediate 1c (10 mmol), 4-(4-morpholino)aniline (12 mmol) and triethylamine (12 mmol) were added sequentially to 50 mL of isopropanol. The mixture was heated and stirred at 70 °C for 8 hours. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the resulting reaction solution was extracted three times with 50 mL of saturated sodium chloride aqueous solution / 50 mL of ethyl acetate. The resulting organic phase was dried with anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. Intermediate 1d was obtained by column chromatography.
[0107] (4) Intermediate 1d (1 mmol) and 2-thiopheneboronic acid (1.25 mmol) were added to 20 mL of N,N-dimethylformamide solvent, followed by potassium carbonate (1.75 mmol) and tetrakis(triphenylphosphine)palladium (0.05 mmol). The mixture was heated and stirred at 100 °C for 10 hours under nitrogen protection. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the reaction solution was extracted three times with 10 mL of saturated sodium chloride aqueous solution / 10 mL of ethyl acetate. The resulting organic phase was dried with anhydrous sodium sulfate, filtered, and the organic phase solvent was removed by rotary evaporation. Intermediate 1e was obtained by column chromatography. (5) Intermediate 1e (1 mmol) and sodium hydride (1.2 mmol) were dissolved in 20 mL of tetrahydrofuran. After stirring in an ice bath for half an hour, iodomethane (1 mmol) was added dropwise. The reaction was monitored by thin-layer chromatography. After the reaction was completed, the reaction solution was extracted three times with 10 mL of saturated sodium chloride aqueous solution / 10 mL of dichloromethane as the extraction solvent. The obtained organic phase was stirred at room temperature, and 500 μL of concentrated hydrochloric acid was added dropwise. The mixture was stirred at room temperature for another 3 hours. The solvent was removed by rotary evaporation to obtain compound 36. The yield was 19.1%.
[0108] The structure is characterized as follows: 1 H NMR (400 MHz, DMSO- d 6) δ 8.51 (s, 1H), 7.85 (d, J = 3.7Hz, 1H), 7.69-7.65 (m, 1H), 7.43-7.32 (m, 4H), 7.16-7.11 (m, 1H), 3.91-3.84(m, 4H), 3.72 (s, 3H), 3.33 (t, J = 4.8 Hz, 4H). 13 C NMR (100 MHz, DMSO- d 6) δ152.01, 141.24, 131.03, 128.97, 127.59, 118.61, 65.63, 50.99. HRMS (ESI)calcd for C 20 H 20 N6OS[M+H] + , 393.1492; found: 393.1496. Technical effect 1. LSD1 inhibitory activity assay The samples described below are purine compounds prepared in Examples 1-36. The preparation process of the sample stock solution is as follows: weigh 1-2 mg of the sample, prepare a 10 mM solution with DMSO as the solvent, store it at 4 ℃ for later use, and obtain the sample stock solution. Dilute it with DMSO to the required concentration during the test to obtain the sample to be tested.
[0109] For the initial screening of LSD1 inhibitory activity of compounds, the 10 mM compound stock solution was first diluted to 800 µM to obtain the test sample. 1.25 µL of the test sample and 96.4 µL of recombinant LSD1 protein were incubated in HEPES buffer at room temperature for 10 min. Then, 1.25 µL of LSD1 substrate H3K4me2 (final concentration 25 µM) was added and incubated at 37 °C for 30 min. Finally, 0.1 µL of 20 mM Amplex Red solution and 1 µL of 550 U / mL horseradish peroxidase solution were added, and the reaction was carried out at room temperature for 5 min for color development. Fluorescence values were detected using a microplate reader at excitation light of 530 nm and emission light of 590 nm. The inhibition rate was calculated using the following formula: The experimental results were calculated using SPSS software. 50 The values are shown in Table 1.
[0110] Table 1. LSD1 inhibitory activity of purine compounds in Examples 1-36 of this invention. 2. Compound 30 promotes MHC-I expression in esophageal cancer cells and enhances T cell-mediated cytotoxicity. To evaluate the effect of compound 30 obtained in Example 30 on T cell-mediated anti-esophageal cancer immune response, this invention used the human esophageal cancer KYSE410 cell line and the LSD1 gene knockout KYSE410 LSD1 KO cell line, and detected the effect using T cell killing assays, flow cytometry, and Western blot methods, including the following steps: T-cell toxicity assay: KYSE410 cells were cultured at 37°C for 5 days using cell culture media containing different concentrations (0, 1, 2, 4 μM) of compound 30. The culture medium was discarded, and the compound 30-treated KYSE410 cells were collected. Activated human T cells were added at an effector-to-target ratio of 5:1 or 10:1 (T cells: esophageal cancer KYSE410 cells) and co-cultured at 37°C for 3 days. After co-culture, the supernatant was discarded, and the viability of adherent tumor cells was quantitatively detected using the sulfonylrhodamine B (SRB) method.
[0111] Flow cytometry detection of MHC-I expression: Esophageal cancer cells KYSE410 and KYSE410 LSD1 KO were cultured at 37°C for 5 days using cells containing 0, 0.5, 1, 2, and 4 μM of compound 30. Cells were then stained with FITC-labeled anti-human HLA-A / B / C antibody, and the fluorescence intensity of MHC-I on the surface of KYSE410 and KYSE410 LSD1 KO cells after treatment with different concentrations of compound 30 was detected.
[0112] Western blot detection of the STAT1 signaling pathway: Cells containing 0, 0.5, 1, 2, and 4 μM of compound 30 were cultured at 37°C for 5 days in esophageal cancer cells (KYSE410). After lysing the cells, proteins were extracted, and protein expression levels were detected using anti-STAT1 and anti-P-STAT1 antibodies.
[0113] STAT1 knockdown assay: 3 µL of KeygenMax 3000 transfection reagent (purchased from Keygen Biosciences) was added to 50 µL of serum-free culture medium. Simultaneously, 50 pM of human STAT1 siRNA sequence was added to 50 µL of serum-free culture medium. The diluted transfection reagent and STAT1 siRNA were then mixed and incubated at room temperature for 10 min. The transfection reagent-siRNA mixture was added to the cell culture medium in 6-well plates, and after 6 h, the medium was replaced with normal cell culture medium, and the cells were cultured for another 48 h. A STAT1 knockdown KYSE410 cell model was constructed by transfecting STAT1 siRNA into esophageal cancer KYSE410 cells to interfere with STAT1 expression. KYSE410 and KYSE410 STAT1KD cells were cultured at 37 °C for 5 days in cell culture medium containing compound 30 (4 μM). Changes in MHC-I expression on the cell surface were detected by flow cytometry.
[0114] The results are as follows Figure 1As shown, data are expressed as mean ± standard deviation. *p<0.05, **p<0.01, and ***p<0.001 were considered statistically significant compared to the control group. It can be seen that the T cell toxicity assay showed that at effector-target ratios of 5:1 and 10:1, compared to the control group, T cells pretreated with compound 30 significantly enhanced the efficacy against KYSE410 esophageal cancer cells, exhibiting a concentration-dependent effect. Figure 1 In Part A of the study, there were statistically significant differences (P<0.05, P*<0.01, P<0.001). Flow cytometry results ( Figure 1 Part B of the study showed that compound 30 dose-dependently increased MHC-I expression on the surface of KYSE410 cells; however, no such effect was observed in LSD1 KO cells, indicating that compound 30 upregulates MHC-I by targeting and inhibiting LSD1. Western blot results ( Figure 1 Part C showed that compound 30 dose-dependently upregulated STAT1 and P-STAT1 protein levels, suggesting that it exerts its immunomodulatory effect by activating the STAT1 signaling pathway. STAT1 knockdown assay ( Figure 1 The DE section further confirmed that the MHC-I upregulation effect induced by compound 30 was significantly reversed by the knockdown of STAT1, confirming that compound 30 enhances T cell-mediated anti-tumor immune responses through the STAT1-MHC-I signaling axis.
[0115] 3. Inhibitory effect of compound 30 on the growth of esophageal cancer syngeneic subcutaneous xenografts in immunocompetent mice. To evaluate the in vivo antitumor efficacy of compound 30, an syngeneic subcutaneous xenograft model was established using immunocompetent C57BL / 6 mice with mouse esophageal cancer mEC25 cells, including the following steps: Approximately 1×10 6 One mEC25 cell was injected into the right axilla of a mouse, and the tumor volume was increased to approximately 100 mm. 3 Mice were randomly divided into four groups. Compound 30 was dissolved in 0.5% sodium carboxymethyl cellulose. The four groups of mice were then set as follows: a control group treated with 0.5% sodium carboxymethyl cellulose solution, and groups receiving oral administration of Compound 30 at doses of 10, 20, and 40 mg / kg / day for 14 consecutive days. Tumor volume and body weight were recorded daily. After the administration period, the tumors were removed and weighed. Heart, liver, spleen, lungs, and kidneys were collected for H&E staining, and serum liver and kidney function indicators such as AST, ALT, UA, and Cre were measured.
[0116] The results are as follows Figure 2As shown, data are expressed as mean ± standard deviation. *p<0.05, **p<0.01, and ***p<0.001 were considered statistically significant compared to the control group. It can be seen that, compared to the control group, tumor volume and tumor weight were significantly reduced in all treatment groups of compound 30 in a dose-dependent manner. Figure 2 (AC portion). During the administration period, the body weight of mice in each group steadily increased ( Figure 2 (Part D), H&E staining results showed no obvious pathological changes in any of the major organs. Figure 2 In the middle E section, there were no significant differences in liver and kidney function indicators compared to the control group. Figure 2 (Part F of the study). At the administered dose and over the 14-day dosing period, compound 30 demonstrated significant in vivo antitumor activity, and no significant toxicity-related changes were observed, indicating good preliminary in vivo tolerability.
[0117] 4. Verification of reversible inhibition The reversibility of a compound is determined using a dilution method, which includes the following steps: Dose-dependent enzyme inhibitors can strongly inhibit enzyme activity at high concentrations, but are ineffective at low concentrations. Therefore, reversible inhibitors, when incubated with enzymes at high concentrations and then infinitesimally diluted to obtain low concentrations of both inhibitor and enzyme, allow enzyme activity to be restored. Specifically, 2.5 µL of a 10 µM compound 30 was mixed with 192.8 µL of recombinant LSD1 protein to form a 200 µL system. After incubation at 37°C for 1 hour, 97.65 µL of the mixture was used to detect LSD1 activity. Additionally, the mixture was diluted 100-fold, and another 97.65 µL of this solution was used to detect LSD1 activity. A 10 µM irreversible LSD1 inhibitor group (ORY-1001) was used as a positive control, and the LSD1 protein group served as a blank control.
[0118] The results are as follows Figure 3 As shown, 10 µM of compound 30 effectively inhibited LSD1 activity. After a 100-fold dilution of the mixture of compound 30 and LSD1, LSD1 activity was significantly restored. Meanwhile, the positive control group ORY-1001 irreversibly inhibited LSD1 activity. Figure 3 Therefore, compound 30 exhibits reversible inhibition of LSD1.
[0119] The above results collectively indicate that compound 30 possesses good LSD1 inhibitory activity, significantly enhances T cell-mediated anti-tumor immune responses in vitro, and dose-dependently inhibits tumor growth in an immunocompetent C57BL / 6 mouse subcutaneous esophageal cancer xenograft model. Furthermore, it did not cause significant weight loss, pathological changes in major organs, or abnormal liver and kidney function at any of the tested doses (10, 20, and 40 mg / kg), indicating that compound 30 has good preliminary in vivo tolerability under the experimental conditions. Most of the purine compounds provided in this invention exhibit good inhibitory activity against LSD1. In particular, compound 30 can enhance T cell-mediated tumor killing effects by targeting and inhibiting the LSD1-activated STAT1 signaling pathway, upregulating MHC-I expression on the surface of esophageal cancer cells, and thus demonstrating significant in vivo anti-tumor activity and good preliminary tolerability. This invention provides a new lead compound for the development of LSD1-targeted anti-tumor drugs and also provides a new molecular basis and experimental evidence for LSD1-targeted tumor immunotherapy strategies.
[0120] The above are merely preferred embodiments of the present invention, but the scope of protection of the present invention is not limited thereto. Any variations or substitutions that can be easily conceived by those skilled in the art within the scope of the technology disclosed in the present invention should be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.
Claims
1. A purine compound, characterized in that, Its structural formula is shown in Formula I: ; Wherein, the R 1 Selected from phenyl, substituted phenyl, five-membered heteroaryl or six-membered heteroaryl; X is selected from NH, NMe, or does not exist; When X is NH or NMe, R 2 Selected from aryl or substituted aryl; When X does not exist, R 2 Selected from nitrogen-containing heterocyclic groups that can be directly linked to the purine nucleus.
2. A purine compound according to claim 1, characterized in that, The R 1 Selected from , , , , , , , , , , , , , , , , , , , , , , , and One of them.
3. A purine compound according to claim 1, characterized in that, The R 2 Selected from , , , , , , , , , and One of them.
4. A method for preparing a purine compound as described in any one of claims 1-3, characterized in that, Includes the following steps: (1) 2,6-Dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine was subjected to a nucleophilic substitution reaction with an amine compound under alkaline conditions to obtain intermediate 1d; (2) The intermediate 1d was coupled with the boric acid substrate under the action of base and palladium catalyst in a Suzuki coupling reaction, and then post-processed to obtain the purine compound.
5. The preparation method according to claim 4, characterized in that, The amine compound mentioned in step (1) is selected from one or more of N,N-diethyl-p-phenylenediamine, N,N-dimethyl-p-phenylenediamine, p-phenylenediamine, 4-methoxyaniline, 4-methanesulfonamide aniline, 4-(4-methylpiperazine)aniline, 4-(4-morpholino)aniline, 4-piperidine aniline, 1-Boc-4-(4-aminophenyl)piperazine, morpholine, and piperazine; The base is triethylamine.
6. The preparation method according to claim 4, characterized in that, The nucleophilic substitution reaction described in step (1) is carried out at a temperature of 70-100℃ for 8 hours.
7. The preparation method according to claim 4, characterized in that, The boric acid substrate mentioned in step (2) is selected from one of phenylboronic acid, substituted phenylboronic acid, or heteroarylboronic acid; The alkali is potassium carbonate; The palladium catalyst is either bis(tri-tert-butylphosphine)palladium or tetra(triphenylphosphine)palladium.
8. The preparation method according to claim 4, characterized in that, The temperature of the Suzuki coupling reaction in step (2) is 100-120℃ and the time is 8-12h.
9. The preparation method according to claim 4, characterized in that, The post-processing described in step (2) includes a protecting group removal process: The product of the Suzuki coupling reaction was dissolved in an organic solvent, and then concentrated hydrochloric acid was added dropwise to carry out acid-catalyzed hydrolysis at room temperature to complete the hydrochloric acid-catalyzed removal of the protecting group. or, The product of the Suzuki coupling reaction was mixed with sodium hydride in an organic solvent for deprotonation, followed by the dropwise addition of iodomethane for nucleophilic substitution. After the reaction was completed, the mixture was extracted, and hydrochloric acid was added dropwise to the resulting organic phase for catalytic hydrolysis to complete the removal of protecting groups.
10. The use of a purine compound as described in any one of claims 1-3 in the preparation of an antitumor drug targeting LSD1.
